BRAF and non-small cell lung carcinoma: The main limitation of this study is the availability of only two patients treated with erlotinib, reflecting the low prevalence of BRAF class 3 mutations in NSCLC (approximately 1%) and the historically limited use of erlotinib in later lines of treatment for EGFR wild-type patients.